Skip to main content

Advertisement

SpringerLink
Log in

Phase II Trial: Undifferentiated Versus Differentiated Autologous Mesenchymal Stem Cells Transplantation in Egyptian Patients with HCV Induced Liver Cirrhosis

  • Published:
Stem Cell Reviews and Reports Aims and scope Submit manuscript

Abstract

The study was aimed to evaluate the effect of autologous transplantation of BM-derived undifferentiated and differentiated MSCs in cirrhotic patients following chronic hepatitis C virus infection. Twenty-five patients with Child C liver cirrhosis, MELD score >12 were included. They were divided into 2 groups. Group I, the MSCs group (n = 15), this group was subdivided into two subgroups: Ia & Ib (undifferentiated and differentiated respectively). Group II (control group; n = 10) involved patients with cirrhotic liver under conventional supportive treatment. Ninety ml BM was aspirated from the iliac bone for separation of MSCs. Surface expression of CD271, CD29 and CD34 were analyzed using flowcytometry. Hepatogenesis was assessed by immunohistochemical expression of OV6, AFP and albumin. Finally approximately 1 million MSCs/Kg were suspended in saline and were placed in blood bag and injected slowly intravenously over 15 min at a rate of 5 drops/min in one session. Follow up of patients at 3 and 6 months postinfusion revealed partial improvement of liver function tests with elevation of prothrombin concentration and serum albumin levels, decline of elevated bilirubin and MELD score in MSCs group. Statistical comparisons between the two subgroups (group Ia & Ib) did not merit any significant difference regarding clinical and laboratory findings. In conclusion: Bone marrow MSCs transplantation either undifferentiated or differentiated can be used as a potential treatment for liver cirrhosis.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Fig. 1

Similar content being viewed by others

Abbreviations

BM:

Bone marrow

MSCs:

Mesenchymal stem cells

MELD score:

Model of End–Stage Liver Disease

HSCs:

Hematopoietic stem cells

HSC:

Hepatic stellate cells

References

  1. Christoforou, N., & Gearhart, J. D. (2007). Stem cells and their potential in cell-based cardiac therapies. Progress in Cardiovascular Diseases, 49, 396–413.

    Article  PubMed  CAS  Google Scholar 

  2. Chop, M., & Li, Y. (2002). Treatment of neural injury with marrow stromal cells. Lancet Neurology, 1, 92–100.

    Article  Google Scholar 

  3. Pittenger, M. F. (2008). Mesenchymal stem cells from adult bone marrow. Methods in Molecular Biology, 449, 27–44.

    PubMed  CAS  Google Scholar 

  4. Satija, N. K., Singh, V. K., Verma, Y. K., et al. (2009). Mesenchymal stem cell-based therapy: a new paradigm in regenerative medicine. Journal of Cellular and Molecular Medicine, 13(11–12), 4385–4402.

    Article  PubMed  CAS  Google Scholar 

  5. Silva, W. A., Covas, D. T., Panepucci, R. A., et al. (2003). The profile of gene expression of human marrow mesenchymal stem cells. Stem Cells, 21, 661–669.

    Article  PubMed  CAS  Google Scholar 

  6. Bühring, H. J., Battula, V. L., Treml, S., et al. (2007). Novel markers for the prospective isolation of human MSC. Annals of the New York Academy of Sciences, 1106, 262–271.

    Article  PubMed  Google Scholar 

  7. Gronthos, S., Zannettino, A. C., Hay, D. J., et al. (2003). Molecular and cellular characterization of highly purified stromal stems derived from human bone marrow. Journal of Cell Science, 116, 1827–1835.

    Article  PubMed  CAS  Google Scholar 

  8. Boiret, N., Rapatel, C., Veyrat-Masson, R., et al. (2005). Characterization of nonexpanded mesenchymal progenitor cells from normal adult human bone marrow. Experimental Hematology, 33, 219–225.

    Article  PubMed  CAS  Google Scholar 

  9. Baddoo, M., Hill, K., Wilkinson, R., et al. (2003). Characterization of mesenchymal stem cells isolated from murine bone marrow by negative selection. Journal of Cellular Biochemistry, 89, 1235–1249.

    Article  PubMed  CAS  Google Scholar 

  10. Fang, B., Shi, M., Liao, L., et al. (2004). Systemic infusion of FLK1 mesenchymal stem cells ameliorates carbontetrachloride-induced liver fibrosis in mice. Transplantation, 78, 83–88.

    Article  PubMed  CAS  Google Scholar 

  11. Freeman, R. B., Steffick, D. E., Guidinger, M. K., et al. (2008). Liver and intestine transplantation in the United States, 1977–2006. American Journal of Transplantation, 8, 958–976.

    Article  PubMed  Google Scholar 

  12. Parekkadan, B., Poll, D. V., Suganuma, K., et al. (2007). Mesenchymal stem cell-derived molecules reverse fulmimant hepatic failure. PLoS One, 2(9), 941–949.

    Article  Google Scholar 

  13. Dai, L., Li, H. Y., Guan, L., et al. (2008). The therapeutic potential of bone marrow-derived mesenchymal stem cells on hepatic cirrhosis. Stem Cell Research, 2, 16–25.

    Article  PubMed  Google Scholar 

  14. Libbrecht, L., Desmet, V., Van Damme, B., et al. (2000). The immunohistochemical phenotype of dysplastic foci in human liver: correlation with putative progenitor cells. Journal of Hepatology, 33, 76–84.

    Article  PubMed  CAS  Google Scholar 

  15. Xiao, J. C., Ruck, P., Adam, A., et al. (2003). Small epithelial cells in human liver cirrhosis exhibit features of hepatic stem like cells: immunohistochemical, electron microscopic and immunoelectron microscopic findings. Histopathology, 42, 141–149.

    Article  PubMed  Google Scholar 

  16. Svegliati-Baroni, G., De Minicis, S., & Marzioni, M. (2008). Hepatic fibrogenesis in response to chronic liver injury: novel insights on the role of cell-to-cell interaction and transition. Liver International, 28(8), 1052–1064.

    Article  PubMed  CAS  Google Scholar 

  17. Darwish, M. A., Faris, R., Darwish, N., et al. (2001). Hepatitis C and cirrhotic liver disease in the Nile delta of Egypt: a community-based study. The American Journal of Tropical Medicine and Hygiene, 64, 147–153.

    PubMed  CAS  Google Scholar 

  18. Li, J., Li, M., Niu, B., et al. (2011). Therapeutic potential of stem cell in liver regeneration. Frontiers of Medicine, 5(1), 26–32.

    Article  PubMed  CAS  Google Scholar 

  19. Kale, S. (2003). Bone marrow stem cells contribute to repair of the ischemically injured renal tubule. The Journal of Clinical Investigation, 112, 42–49.

    PubMed  CAS  Google Scholar 

  20. Thiese, N. D. (2006). Emergent themes of liver stem cell biology: niche, quiescence, self-renewal, and plasticity. American Journal of Physiology—Gastrointestinal and Liver Physiology, 290, 189–193.

    Article  Google Scholar 

  21. Sarah, S., Tamora, V., Peggy, P., et al. (2006). Sequential exposure to cytokines reflecting embryogenesis: the key for in vitro differentiation of adult bone marrow stem cells into functional hepatocyte-like cells. Toxicological Sciences, 94(2), 330–341.

    Article  Google Scholar 

  22. Lange, C., Bassler, P., Lioznov, M. V., et al. (2005). Hepatocytic gene expression in cultured rat mesenchymal stem cells. Transplantation Proceedings, 37, 276–279.

    Article  PubMed  CAS  Google Scholar 

  23. Terai, S., Ishikawa, T., Omori, K., et al. (2006). Improved liver function in patients with liver cirrhosis after autologous bone marrow cell infusion therapy. Stem Cells, 24, 2292–2298.

    Article  PubMed  CAS  Google Scholar 

  24. Mohamadnejad, M., Alimoghaddam, K., Mohyeddin-Bonab, M., et al. (2007). Phase 1 trial of autologous bone marrow mesenchymal stem cell transplantation in patients with decompensated liver cirrhosis. 10(4), 459–466.

  25. Abdel Aziz, M. T., Atta, H., Mahfouz, S., et al. (2007). Therapeutic potential of bone marrow-derived mesenchymal stem cells on experimental liver fibrosis. Clinical Biochemistry, 40, 893–899.

    Article  PubMed  CAS  Google Scholar 

  26. Zhao, D. C., Lei, J. X., Chen, R., et al. (2005). Bone marrow-derived mesenchymal stem cells protect against experimental liver fibrosis in rat. World Journal of Gastroenterology, 14, 3431–3440.

    Google Scholar 

  27. Aquino, J. B., Bolontrade, M. F., Garcia, M. G., et al. (2010). Mesencymal stem cells as therapeutic tools and gene carrirers in hepatocellular carcinoma and liver fibrosis. Gene Therapy, 17, 62–708.

    Article  Google Scholar 

  28. Chen, X., Li, Y., Wang, L., et al. (2002). Ischemic rat brain extracts induce human marrow stromal cell growth factor production. Neuropathology, 22, 275–279.

    Article  PubMed  Google Scholar 

  29. Zhang, B., Inagaki, M., Jiang, B., et al. (2009). Effects of BM and hepatocyte transplantation on liver injury. Journal of Surgical Research, 157(1), 71–80.

    Article  PubMed  Google Scholar 

  30. Oyagi, S., Hirose, M., Kojima, M., et al. (2006). Therapeutic effect of transplanting HGF-treated bone marrowmesenchymal cells into CCl4-injured rats. Journal of Hepatology, 44, 742–748.

    Article  PubMed  CAS  Google Scholar 

  31. Yu, Y., Lu, L., Qian, X., et al. (2010). Antifibrotic effect of hepatocyte growth factor-expressing mesenchymal stem cells in small-for-size liver transplant rats. Stem Cells and Development, 19(6), 903–914.

    Article  PubMed  CAS  Google Scholar 

  32. Fox, I. J., & Strom, S. C. (2008). To be or not to be: generation of hepatocytes from cells outside the liver. Gastroenterology, 134, 878–881.

    Article  PubMed  Google Scholar 

  33. Di Bonzo, L. V., Ferrero, I., Cravanzola, C., et al. (2008). Human mesenchymal stem cells as a two-edged sword in hepatic regenerative medicine: engraftment and hepatocyte differentiation versus profibrogenic potential. Gut, 57, 223–231.

    Article  PubMed  Google Scholar 

Download references

Acknowledgment

The authors would like to thank Kasr El-Aini hospital for in part supporting of this study. We also thank El-Ansary private laboratories, our patients for their willing participation in our research.

Disclosure

The authors of this manuscript have no conflicts of interest to disclose.

Author information

Authors and Affiliations

  1. Department of Clinical Pathology, Kasr El-Aini, Cairo University, Cairo, Egypt

    Mervat El-Ansary & Samah Abdel-Hamid

  2. Department of Haematology, Theodor Bilharz Research Institute, Giza, Egypt

    Iman Abdel-Aziz, Salwa Teaema & Marwa Wahdan

  3. Department of Hepatology and Gastroenterology, Kasr El-Aini, Cairo University, Cairo, Egypt

    Sherif Mogawer

  4. Department of Pathology, Theodor Bilharz Research Institute, Giza, Egypt

    Olfat Hammam

Authors
  1. Mervat El-Ansary
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Iman Abdel-Aziz
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Sherif Mogawer
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Samah Abdel-Hamid
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Olfat Hammam
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Salwa Teaema
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Marwa Wahdan
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Samah Abdel-Hamid.

Additional information

This study is supported in part by fund from Kasr El-Aini hospital

Rights and permissions

Reprints and permissions

About this article

Cite this article

El-Ansary, M., Abdel-Aziz, I., Mogawer, S. et al. Phase II Trial: Undifferentiated Versus Differentiated Autologous Mesenchymal Stem Cells Transplantation in Egyptian Patients with HCV Induced Liver Cirrhosis. Stem Cell Rev and Rep 8, 972–981 (2012). https://doi.org/10.1007/s12015-011-9322-y

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s12015-011-9322-y

Keywords

Search

Navigation